Sunesis Continues Rally

Shares of Sunesis Pharmaceuticals Inc. (Nasdaq: SNSS) rallied for a third day by rising 23 cents to $1.95 after the company reported upbeat clinical trial data for its cancer treatment Voreloxin last week.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.